<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309136</url>
  </required_header>
  <id_info>
    <org_study_id>AHNATHY</org_study_id>
    <nct_id>NCT04309136</nct_id>
  </id_info>
  <brief_title>Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer</brief_title>
  <official_title>The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment in Locally Advanced Thyroid Cancer: a Single-arm Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid
      cancer in the neoadjuvant setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at the time point of 6 weeks</time_frame>
    <description>ORR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0/1 resection rate</measure>
    <time_frame>at the time of surgery</time_frame>
    <description>R0/1 resection rate if operable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at the time point of 6 weeks</time_frame>
    <description>DCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>from the first drug administration to within 90 days after surgery</time_frame>
    <description>AEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>All patients will receive Anlotinib for two cycles of neoadjuvant treatment</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>Perform surgery if operable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>core needle biopsy</intervention_name>
    <description>Perform core needle biopsy if inoperable after neoadjuvant therapy</description>
    <arm_group_label>Neoadjuvant Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient volunteered to participate in the study and signed an informed consent
             form;

          -  Pathologically diagnosed locally advanced thyroid cancer, including papillary thyroid
             cancer, medullary cancer, follicular cancer, poorly differentiated cancer, etc.,
             require surgical resection with or without distant metastasis;

          -  Preoperative assessment of invasion or adhesion of at least one of the following
             structures / organs, including: trachea, esophagus, common carotid artery, larynx,
             anterior vertebral fascia, brachial plexus, intended for surgical treatment;

          -  Have at least one measurable lesion (RECIST 1.1);

          -  Age 14-80 years, Eastern Cooperative Oncology Group (ECOG) score 0-1;

          -  The main organ functions meet the following criteria within 7 days before treatment:

               1. Standard blood test (without blood transfusion within 14 days):Hemoglobin (HB)
                  ≥90g / L;Absolute neutrophil value (ANC) ≥ 1.5 × 109 / L;Platelet (PLT) ≥80 × 109
                  / L

               2. Biochemical inspection must meet the following standards:Total bilirubin (TBIL) ≤
                  1.5 times the upper limit of normal value (ULN); Alanine aminotransferase (ALT)
                  and aspartate aminotransferase (AST) ≤ 2.5 ULN, if with liver metastases, ALT and
                  AST ≤ 5 ULN; Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 60ml
                  / min;

               3. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ the
                  lower limit of normal value (50%).

          -  Women of childbearing age should agree to use contraceptives during the study and
             within 6 months after the study; negative serum or urine pregnancy tests within 7 days
             before study enrollment; men should agree to use contraception during the study period
             and within 6 months after the end of the study period.

        Exclusion Criteria:

          -  Previously used anlotinib or similar VEGFR-TKI small molecule drugs, such as
             vandetanib, cabozantinib, lenvatinib, sunitinib, sorafenib and etc.

          -  Received external radiation therapy or iodine-131 therapy within the past 3 months; or
             planned systemic anti-tumor therapy during this study;

          -  Pathologically confirmed non-thyroid epithelial cell-derived malignant tumors
             (including lymphoma, metastatic cancer, sarcoma, etc.);

          -  With other uncontrolled / under treatment malignancies;

          -  Those who have multiple factors (such as inability to swallow) that affect oral
             medication;

          -  With pleural effusion or ascites, causing respiratory syndrome (≥CTC AE level 2
             dyspnea [level 2 dyspnea refers to shortness of breath when a small amount of
             activity; affecting instrumental daily activities]);

          -  Patients with any severe and / or uncontrolled illness, including:

               1. Patients whose blood pressure is still unsatisfactory with a blood pressure
                  medication (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100
                  mmHg);

               2. Patients with myocardial ischemia or myocardial infarction of grade I or higher
                  and congestive heart failure of grade 2 or higher (New York Heart Association
                  (NYHA) classification);

               3. Sinus bradycardia; or atrioventricular block of more than two degrees, or sinus
                  arrest (except for pacemakers); arrhythmia (including QTC ≥480ms); need to be
                  used together to extend QTc interval drugs, including those for antiarrhythmic
                  treatment;

               4. Active or uncontrolled severe infection (≥CTC AE level 2 infection);

               5. Patients with cirrhosis, decompensated liver disease, active hepatitis or chronic
                  hepatitis;

               6. Renal failure requires hemodialysis or peritoneal dialysis;

               7. Have a history of immunodeficiency, including those who are HIV positive or have
                  other acquired or congenital immunodeficiency diseases, or have a history of
                  organ transplantation;

               8. Poor blood glucose control in diabetic patients (fasting blood glucose (FBG)&gt;
                  10mmol / L);

               9. Urine routine indicates urinary protein ≥ ++, and the 24-hour urine protein
                  quantification is greater than 1.0 g.

          -  received major surgical treatment, incisional biopsy or obvious traumatic injury
             within 28 days before enrollment;

          -  Patients whose imaging showed that the tumor had invaded the important blood vessels
             or the researchers judged that the tumor was likely to invade important blood vessels
             during the subsequent study period and caused fatal bleeding;

          -  Patients with any signs or history of bleeding regardless of severity; patients with
             any bleeding or bleeding event ≥ CTCAE level 3 within 4 weeks prior to grouping with
             unhealed wounds, ulcers or fractures

          -  Arterial / venous thrombosis events, such as cerebrovascular accidents (including
             transient ischemic attacks), deep vein thrombosis and pulmonary embolism within 6
             months;

          -  History of aneurysm;

          -  Those with a history of epilepsy or neurological disorders with ataxia in need of
             treatment;

          -  People with a history of psychotropic substance abuse who are unable to quit or have
             mental disorders;

          -  Those with a history of peripheral nervous system disease and muscle strength below 3;

          -  Those who have participated in other clinical trials of anti-tumor drugs within four
             weeks or are conducting other clinical trials;

          -  According to the investigator's judgment, there are concomitant diseases that
             seriously endanger the safety of patients or affect patients to complete the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yu Wang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>65805</phone_ext>
    <email>neck130@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nai-si Huang, M.D.</last_name>
    <phone>86-021-64175590</phone>
    <phone_ext>67816</phone_ext>
    <email>huangnaisi@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Wang, M.D.</last_name>
      <phone>86-021-64175590</phone>
      <phone_ext>65805</phone_ext>
      <email>neck130@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thyroid cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>Anlotinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

